Preclinical Data Highlights Potential of Ikarovec's Bicistronic Gene Therapy Approach in Common Causes of Vision Loss
- Studies presented at leading ophthalmology and gene therapy conferences demonstrate therapeutic potential in geographic atrophy and wet AMD, leading causes of legal blindness
- This single-administration gene therapy approach could replace frequent eye injections for geographic atrophy and wet AMD patients
- The lead candidate IKAR-001 (previously known as IKC159V) will proceed to a geographic atrophy clinical trial supported by studies showing preservation of cells critical for vision